Iain D. Dukes - Apr 1, 2024 Form 4/A Insider Report for Traws Pharma, Inc. (TRAW)

Role: Executive Chairman, Director
Signature: /s/ Iain Dukes
Stock symbol: TRAW
Transactions as of: Apr 1, 2024
Transactions value $: $0
Form type: 4/A
Date filed: 8/7/2024, 03:47 PM
Date Of Original Report: Apr 3, 2024
Previous filing: Mar 5, 2024
Next filing: Jun 10, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRAW	Common Stock	Award		+67.5K	+101.22%		134K	Apr 1, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On April 3, 2024, the reporting person filed a Form 4 that inadvertently reported the number of shares of common stock (the "Common Stock") of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) underlying a grant of restricted stock units as 67,550 instead of 67,500. Nevertheless, the number of shares of Common Stock beneficially owned following the reported transaction was correctly reported in the original Form 4 as 134,187.
F2	Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis.

Content

On April 3, 2024, the reporting person filed a Form 4 that inadvertently reported the number of shares of common stock (the "Common Stock") of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) underlying a grant of restricted stock units as 67,550 instead of 67,500. Nevertheless, the number of shares of Common Stock beneficially owned following the reported transaction was correctly reported in the original Form 4 as 134,187.

Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of Common Stock on a one-for-one basis.